Akeso Earnings Call Transcripts

Fiscal Year 2024

Earnings Call: H2 2024
2024 saw strong revenue growth, major drug approvals, and strategic NRDL inclusion for key bispecific antibodies, supported by robust clinical data and pipeline expansion. Operating losses narrowed, and the company is well-capitalized for further growth and global partnerships.

Read full transcript →

Annual report
Earnings release
Slides
7th Annual Evercore ISI HealthCONx Healthcare Conference

Management highlighted an $8B Hong Kong valuation, global expansion plans, and key clinical milestones for ivonescimab and cadonilimab. Proprietary bispecific antibody technology and a robust pipeline support ambitions beyond China, with major data readouts expected by 2026.

Read full transcript →